Kura Oncology (NASDAQ:KURA) Cut to "Hold" at Stifel Nicolaus

Stifel Nicolaus lowered shares of Kura Oncology (NASDAQ:KURA - Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday, MarketBeat reports. They currently have $19.00 price target on the stock, down from their prior price target of $26.00.

A number of other research analysts also recently issued reports on KURA. Cantor Fitzgerald reissued an overweight rating on shares of Kura Oncology in a research report on Monday, September 9th. HC Wainwright reissued a buy rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. JMP Securities reissued a market outperform rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Wedbush reissued an outperform rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Friday, August 9th. Finally, StockNews.com downgraded shares of Kura Oncology from a hold rating to a sell rating in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $29.20.

Kura Oncology Trading Down 2.8 %

Shares of NASDAQ KURA traded down $0.52 during mid-day trading on Monday, hitting $18.06. The stock had a trading volume of 839,681 shares, compared to its average volume of 912,769. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. Kura Oncology has a 1 year low of $7.41 and a 1 year high of $24.17. The business has a 50 day moving average price of $19.58 and a two-hundred day moving average price of $20.27. The firm has a market cap of $1.38 billion, a P/E ratio of -8.32 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same quarter in the previous year, the company earned ($0.53) earnings per share. Kura Oncology's revenue was up .0% compared to the same quarter last year. On average, equities analysts anticipate that Kura Oncology will post -2.45 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company's stock valued at $86,726,000 after buying an additional 28,212 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company's stock worth $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Armistice Capital LLC boosted its stake in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock worth $48,386,000 after purchasing an additional 302,000 shares in the last quarter. Artal Group S.A. boosted its stake in Kura Oncology by 8.6% in the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company's stock worth $40,951,000 after purchasing an additional 151,828 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company's stock worth $35,653,000 after purchasing an additional 577,732 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.